Five Indian drugmakers begin joint trial of Merck & Co’s COVID-19 drug
Five Indian generic drugmakers, including Cipla and Dr Reddy’s Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co’s anti-viral drug to treat mild COVID-19 in non-hospitalized patients in India.
Between March and April, each of these companies, which also include Sun Pharmaceutical Industries, Torrent Pharmaceuticals and privately held Emcure Pharmaceuticals, partnered with Merck to expand production of the drug, molnupiravir.
For more coronavirus news, visit our dedicated page.
The partnership gives the companies license to supply molnupiravir to India and more than 100 low- and middle-income countries following approvals or emergency authorization by local regulatory agencies, Merck said in late April.
On Tuesday, the Indian companies said they will jointly sponsor, supervise and monitor the clinical trial in the country, expected to take place between June and September this year in 1,200 patients.
They will then independently approach regulatory authorities for approval to manufacture and supply the drug in India.
Molnupiravir is an antiviral therapy Merck is developing with Ridgeback Biotherapeutics for the treatment of non-hospitalized COVID-19 patients.
Coronavirus cases in India have declined from a devastating peak in April and May. However, health experts have said that the country should brace for a third wave by October.
India’s Modi urges people to get vaccinated amid Delta COVID-19 variant concerns
African Union seeks Covishield approval for EU COVID-19 certificate
Turkey halts flights from six countries due to COVID-19 variants
India faces antifungal drug shortage as rare complication adds to COVID-19 woesIndia said on Friday it was working to alleviate a shortage of a medicine used to treat a rare fungal disease hitting COVID-19 patients as its ... Coronavirus
Supply of COVID-19 drug remdesivir catching up with demand in India: CiplaIndia’s Cipla said on Saturday that its manufacturing of the COVID-19 remdesivir drug was beginning to catch up with demand after the company sought ... Coronavirus
S. Korean drugmaker says trial shows antibody COVID-19 treatment to be effectiveSouth Korean drugmaker Celltrion Inc on Monday announced positive results for its experimental antibody COVID-19 treatment that it said was safe and ... Coronavirus
Asia’s synthetic drug trade expanded amid COVID-19 pandemicDrug traffickers in East and Southeast Asia found ways to evade COVID-19 curbs to boost trade and diversify production, with Cambodia emerging as a ... Coronavirus